Answers are grounded in this paper and cite their sources.
TDRM prevalence overall and for individual drug classes remained stable during 2014-2018; transmitted INSTI resistance was uncommon. Continued population-level monitoring of INSTI and NRTI mutations, especially M184V and K65R, is warranted amidst expanding use of second-generation INSTIs and PrEP.
No takes yet. Share an insight, caveat, or question.
McClung et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: